Photo by nci from unsplash
BACKGROUND CDK4/6-dependent cell-cycle regulation is disrupted in 78% of glioblastoma (GBM) patients and novel CDK4/6 inhibitors have shown anti-tumor activity in animal models. To explore the utility of ribociclib, a… Click to show full abstract
BACKGROUND CDK4/6-dependent cell-cycle regulation is disrupted in 78% of glioblastoma (GBM) patients and novel CDK4/6 inhibitors have shown anti-tumor activity in animal models. To explore the utility of ribociclib, a selective CDK4/6-inhibitor, in treating recurrent GBM patients, we conducted a phase 0/II clinical trial ({"type":"clinical-trial","attrs":{"text":"NCT02933736","term_id":"NCT02933736"}}NCT02933736) to examine plasma and tumor pharmacokinetics (PK) and pharmacodynamics (PD).
Keywords:
ribociclib patients;
tumor pharmacokinetics;
actr plasma;
plasma tumor;
pharmacokinetics ribociclib;
tumor
Journal Title: Neuro-oncology
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Neuro-oncology
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!